New cell therapy aims to supercharge immune recovery in young cancer patients
NCT ID NCT04640987
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a special cell therapy called T-allo10 can safely help rebuild the immune system in children and young adults (up to age 45) with blood cancers who have received a stem cell transplant. The treatment is given after the transplant to speed up recovery of infection-fighting cells while trying to avoid severe graft-versus-host disease. The study involves 22 participants and aims to find the best dose and check for safety and immune improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lucile Packard Children's Hospital
RECRUITINGPalo Alto, California, 94305, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Could a diet and exercise program help childhood leukemia survivors live healthier?
- Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a Two-Drug combo outsmart a deadly leukemia?
- Can a new pill take on Hard-to-Treat leukemia?